6th Annual Life Science Regulatory Intelligence &
Strategy Conference

Freyr GRI is absolutely delighted to have been able to sponsor and exhibit our Regulatory competencies at the 6th Annual Life Science Regulatory Intelligence & Strategy Conference in Baltimore, USA.

Throughout the duration of the conference, we were privileged to witness engaging discussions and thought-provoking presentations on the influence of AI in the world of Regulatory intelligence and compliance as well as participate in invaluable networking opportunities with top Regulatory Affairs professionals.

Freyr Announces Strategic Alliance with a Swiss-based Food and Beverage Powerhouse

New Jersey, March 22, 2024: Freyr Solutions, the largest, global, Regulatory solutions and services provider announces partnership with a renowned Swiss-based multinational food and beverage processing conglomerate. The collaboration focuses on ensuring Regulatory compliance for 16 SKUs and introducing the customer’s flagship food products in the US market.

Pharma Focus Asia Published Freyr’s Perspective on the Cell and Gene Therapy (CGT) Key Regulatory Insights

The field of medicine holds great promise for Cell and Gene Therapy (CGT), which calls for a strong Regulatory framework. Initiatives by the US FDA and EMA to expedite Regulatory procedures include a rise in CGT applications and creative programs like the Bespoke Gene Therapy Consortium (BGTC) and INTERACT meetings. However, achieving worldwide Regulatory uniformity, maintaining strict clinical trial oversight, and striking a balance between innovation and safety pose significant challenges.

DMF Submission for an Indian Pharmaceutical company

The client was an India API manufacturer that was required to file a DMF Submission within a quick TAT. The Regulatory Submissions experts at Freyr Solutions were skilled in making timely submissions with zero warnings and carried out all the submission activities successfully.   

Explore how Freyr's expertise enabled timely DMF Submission for an INDIA-based biopharmaceutical company while ensuring quality outcomes within tight timelines.

Issued Amendment for an Indian Pharmaceutical company

The client was an Indian pharmaceutical company that was required to file a DMF, annual reports, and amendments of the Submissions within a quick TAT. The Regulatory Submissions experts at Freyr Solutions were skilled in making timely submissions with zero warnings and carried out all the submission activities successfully.

Explore how Freyr's expertise enabled timely DMF, annual reports, and amendments for an INDIA-based biopharmaceutical company while ensuring quality outcomes within tight timelines.

Filing of IND Submissions and Amendments with Zero Errors

A top US-based life sciences consulting firm sought Regulatory assistance from Freyr for filing Investigational New Drug (IND) submissions and amendments with the USFDA.

Freyr successfully completed the end-to-end publishing activities for the project within a tight timeline. With granular document-level publishing (DLP) services, the IND submissions and document amendments were made on time without any errors or warnings from the USFDA.